Latest Middle East News

Vmoto Limited reported an 18% revenue decline to $46.8 million and a $9.9 million net loss in FY25, while accelerating its transformation into a full-stack electric mobility solutions provider with new global partnerships and product innovations.

Senetas Corporation reported a reduced half-year loss with stable revenue, despite export permit delays in the Middle East. The company’s strategic alliance with Nokia and ongoing sovereign encryption developments underpin a positive outlook for FY2026.

Memphasys Limited has advanced its Felix™ System commercial rollout with key regulatory approvals and new international contracts, while trimming operating costs and narrowing losses in the first half of FY2026.

X2M Connect Limited has secured a $3 million capital raise to fund expansion into new markets and reduce debt, following a robust first half of FY26 marked by significant revenue and profit growth.

Harvest Technology Group’s half-year report reveals a 50% revenue decline and a widening net loss, offset by a $6 million funding facility and strategic partnerships.

icetana Limited reports a strong first half of 2026 with recurring revenue up 43%, driven by key partnerships and expanded market reach across APAC and the Middle East.

ReNerve Limited reported a half-year loss of $2.72 million, up 47% from last year, as it expands its nerve repair product portfolio and secures new regulatory approvals in Asia-Pacific.

Qoria Limited reported a 25% revenue increase to nearly $69 million for H1 FY2026 but also a widening net loss of $24.5 million. The company announced a transformative merger with US-based Aura to create a global digital safety leader.

SiteMinder Limited reported a robust 25.5% revenue increase to $131.1 million in H1FY26, alongside a significant reduction in statutory loss to $4.78 million, driven by its Smart Platform strategy and disciplined cost management.

Electro Optic Systems reported a 27% revenue drop to $128.5 million in FY2025 but posted a net profit of $18.6 million, boosted by the sale of EM Solutions. The company strengthened its position with key contract wins and acquisitions, including the UK-based Interceptor business and a conditional deal for MARSS.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing for its lead ophthalmology product, Elate Ocular®, alongside key global partnerships and a $2.4 million capital injection from a major shareholder.

Beamtree Holdings Limited reported a 2% rise in total revenue and a reduced net loss in the first half of FY26, driven by a 10% increase in recurring revenue. The company is advancing AI-powered healthcare products and has initiated a strategic review to unlock shareholder value.